Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00884494 · ClinicalTrials.gov registry record · Phase 1
Ghrelin and Insulin Resistance
A Phase 1 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00884494 is a Phase 1 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT00884494, a Phase 1 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Ghrelin, a hormone produced in the stomach that stimulates hunger and food intake, declines immediately after weight loss surgery. Some studies suggest that ghrelin may worsen an individual's ability to respond to insulin. The purpose of this study is to determine if the decline in ghrelin levels after weight loss surgery contributes to the improvement of insulin sensitivity.
Interventions
- DRUG Ghrelin infusion to assess effects on insulin sensitivity
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-08 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00884494
The ClinicalTrials.gov registry entry for NCT00884494 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ghrelin infusion to assess effects on insulin sensitivity is the first listed.
NCT00884494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00884494 about?
NCT00884494 is a clinical study titled "Ghrelin and Insulin Resistance". Ghrelin, a hormone produced in the stomach that stimulates hunger and food intake, declines immediately after weight loss surgery. Some studies suggest that ghrelin may worsen an individual's ability to respond to insulin. The purpose of this study is to determine if the decline in ghrelin levels af...
What is the current status of trial NCT00884494?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2011-08. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00884494?
The interventions under investigation include: Ghrelin infusion to assess effects on insulin sensitivity (DRUG).
Who is sponsoring clinical trial NCT00884494?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.